At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
Secukinumabdrug
Likely dose
Secukinumab 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Phase 1b Study of Secukinumab in Patients With Moderate to Severe Papulopustular Rosacea
In Brief
A Phase 2 clinical trial evaluating Secukinumab for Papulopustular Rosacea. Completed, enrolled 24 participants across 1 site.
Detailed Summary
This is a study to determine whether secukinumab is a potential therapy for those with papulopustular rosacea. We will observe whether this drug decreases the size and/or amount and severity of the pustules of those who suffer from rosacea.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPapulopustular Rosacea
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 2017
Enrollment StartJun 2017
Primary CompletionJan 2019
TodayJul 2026
First PostedMar 14, 2017
Enrollment StartJun 21, 2017
Primary CompletionJan 25, 2019
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 9.3 years ago
Interventions
Secukinumabdrug
Secukinumab 300 mg administered subcutaneously.